Back to Search
ALI AWADA, PHARMD
PHARMD
Pharmacist
NPI: 1285315051Individual
Specialties, Licenses & Credentials
Research & Publications (20)
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
PMID 19633042·Ann Oncol·2010
3-trial
[Deep non-reactive reversible coma after a Mediterranean neurotoxic fish poisoning].
PMID 19665158·Rev Neurol (Paris)·2010
5-case
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors.
PMID 18956139·Invest New Drugs·2009
3-trial
Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
PMID 19186072·Crit Rev Oncol Hematol·2009
6-review
[Therapeutic consequences of molecular biology advances in oncology].
PMID 19211361·Bull Cancer·2009
6-review
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
PMID 19394894·Lancet Oncol·2009
3-trial
The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce.
PMID 18774306·Crit Rev Oncol Hematol·2009
1-meta
Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients.
PMID 19581819·Melanoma Res·2009
8-other
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
PMID 18446338·Cancer Chemother Pharmacol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3255 OWEN RD
FENTON, MI 48430 - Phone
- (810) 714-2406
Quick Facts
- NPI
- 1285315051
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile